Subscribe to receive our Floor Reports covering all the action on the Texas House and Senate floor!
Relating to a cancer clinical trial participation program.
No fiscal implication to the State is anticipated.
HB 3147 would authorize an independent third-party organization to develop and implement a cancer clinical trial participation program to provide reimbursement to an individual who participates in the program for ancillary costs associated with participation in the trial. The reimbursement would be required to comply with applicable federal and state laws, and be reviewed by the institutional review board associated with the cancer clinical trial for which the reimbursement was provided.
The bill would establish that reimbursement does not constitute an inducement to participate in a cancer clinical trial, is not considered coercion or the exertion of undue influence to participate in a trial, and is meant to accomplish parity in access to cancer clinical trials and remove barriers to participation in trials for financially burdened subjects.
Texas Action remains neutral on HB 3147 because it does not affect our liberty principles.